Literature DB >> 27889048

The use of high-dose estrogens for the treatment of breast cancer.

Herjan J T Coelingh Bennink1, Carole Verhoeven2, Alice E Dutman1, Jos Thijssen3.   

Abstract

Estrogens are known to stimulate the growth of breast cancer but they are also an effective treatment for this disease (this has been termed the 'estrogen paradox'). The fact that estrogens can be an effective treatment for breast cancer is something that has almost been forgotten, whereas the fear for estrogens remains. This paper reviews the use of estrogens for the treatment of breast cancer and identifies possible applications. The data summarised in this review demonstrate that high-dose estrogens are effective for the treatment of advanced breast cancer, both as first-line treatment as well as for treatment after occurrence of endocrine resistance to TAM and AIs. Essential for efficacy is an extended period of estrogen deprivation before the tumour is subject to estrogen treatment (the gap hypothesis). Research on the mechanism of action has shown that apoptosis induced by estrogens is regulated via the estrogen receptor and growth factor signalling pathways. High-dose estrogens have a negative safety image, especially in terms of side-effects and increased rates of cardiovascular disease, but the safety data reviewed in this paper do not give rise to major concerns. Taking into account their side-effect profile together with their observed clinical efficacy, high-dose estrogens should be considered a valuable alternative to chemotherapy in selected patients. Copyright Â
© 2016 The Author(s). Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Breast cancer; Endocrine resistance; Estrogen; Estrogen gap

Mesh:

Substances:

Year:  2016        PMID: 27889048     DOI: 10.1016/j.maturitas.2016.10.010

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  12 in total

1.  XAF1 destabilizes estrogen receptor α through the assembly of a BRCA1-mediated destruction complex and promotes estrogen-induced apoptosis.

Authors:  Ji-Sun Lim; Kyung-Woo Lee; Kyung-Phil Ko; Seong-In Jeong; Byung-Kyu Ryu; Min-Goo Lee; Sung-Gil Chi
Journal:  Oncogene       Date:  2022-04-16       Impact factor: 9.867

2.  Inter-Individual Variation in Response to Estrogen in Human Breast Explants.

Authors:  Karen A Dunphy; Amye L Black; Amy L Roberts; Aman Sharma; Zida Li; Sneha Suresh; Eva P Browne; Kathleen F Arcaro; Jennifer Ser-Dolansky; Carol Bigelow; Melissa A Troester; Sallie S Schneider; Grace Makari-Judson; Giovanna M Crisi; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-03-09       Impact factor: 2.673

Review 3.  Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers.

Authors:  Thu H Truong; Carol A Lange
Journal:  Endocrinology       Date:  2018-12-01       Impact factor: 4.736

4.  Nitric oxide is cytoprotective to breast cancer spheroids vulnerable to estrogen-induced apoptosis.

Authors:  Yana Shafran; Naomi Zurgil; Orit Ravid-Hermesh; Maria Sobolev; Elena Afrimzon; Yaron Hakuk; Asher Shainberg; Mordechai Deutsch
Journal:  Oncotarget       Date:  2017-10-07

5.  Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer.

Authors:  Philipp Y Maximov; Balkees Abderrahman; Sean W Fanning; Surojeet Sengupta; Ping Fan; Ramona F Curpan; Daniela Maria Quintana Rincon; Jeffery A Greenland; Shyamala S Rajan; Geoffrey L Greene; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2018-05-08       Impact factor: 4.436

6.  The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells.

Authors:  Philipp Y Maximov; Balkees Abderrahman; Yousef M Hawsawi; Yue Chen; Charles E Foulds; Antrix Jain; Anna Malovannaya; Ping Fan; Ramona F Curpan; Ross Han; Sean W Fanning; Bradley M Broom; Daniela M Quintana Rincon; Jeffery A Greenland; Geoffrey L Greene; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2020-05-03       Impact factor: 4.436

7.  Prenatal polycyclic aromatic hydrocarbons, altered ERα pathway-related methylation and expression, and mammary epithelial cell proliferation in offspring and grandoffspring adult mice.

Authors:  Debashish Sahay; Susan E Lloyd; Janelle A Rivera; Jacqueline Jezioro; Jacob D McDonald; Masha Pitiranggon; Beizhan Yan; Matthias Szabolcs; Mary Beth Terry; Rachel L Miller
Journal:  Environ Res       Date:  2021-03-04       Impact factor: 6.498

8.  Insights into the Behavior of Triple-Negative MDA-MB-231 Breast Carcinoma Cells Following the Treatment with 17β-Ethinylestradiol and Levonorgestrel.

Authors:  Sebastian Simu; Iasmina Marcovici; Amadeus Dobrescu; Daniel Malita; Cristina Adriana Dehelean; Dorina Coricovac; Flavius Olaru; George Andrei Draghici; Dan Navolan
Journal:  Molecules       Date:  2021-05-08       Impact factor: 4.411

Review 9.  Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Authors:  Osama S Mohammad; Michael D Nyquist; Michael T Schweizer; Stephen P Balk; Eva Corey; Stephen Plymate; Peter S Nelson; Elahe A Mostaghel
Journal:  Cancers (Basel)       Date:  2017-12-06       Impact factor: 6.639

10.  Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies.

Authors:  Kang Wang; Feng Li; Li Chen; Yan-Mei Lai; Xiang Zhang; Hong-Yuan Li
Journal:  Oncotarget       Date:  2017-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.